Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Senator asks Novartis to explain its payments to Cohen, noting FDA approval of cancer drug Novartis made $1.2 million in payments to Cohen's firm during the time that the FDA was deciding whether ...

The complaint details how Novartis allegedly used HeLa cells in the development of its herpes drug Famvir, cancer treatment ...

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 ...

Novartis NVS said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

Novartis confirmed that it has received a binding offer from Siemens Healthineers to buy its molecular imaging business for an undisclosed amount. The Swiss pharma major said Monday that the ...

Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Siemens Healthineers has agreed to buy part of a Novartis business that specialises in producing ...

Swiss drugmaker Novartis said on Saturday it had received a binding offer from Germany’s Siemens Healthineers to acquire its molecular imaging business for Fluorine-18 positron emission ...